Search Results

1ST Biotherapeutics, Inc. announced the first patient dosing in the clinical Phase I/II trial evaluating FB849 in patients with advanced solid tumors.

Aatru Medical, LLC announced that it was awarded 1st Place in Oral Abstracts at the 2024 Spring symposium hosted by the Society for Advanced Wound Care (SAWC).

1ST Biotherapeutics, Inc. announced a Clinical Trial Collaboration and Supply Agreement with MSD, a tradename of Merck & Co., Inc., Rahway, NJ, USA, to evaluate FB849 in combination with MSD’s anti-PD-1 therapy KEYTRUDA® in a Phase I/II clinical trial for the treatment of patients with advanced solid tumors.

Precision Biologics, Inc. will be presented in a poster at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, McCormick Place Convention Center, Chicago, Illinois, USA, June 1st, 2024.

InflaRx N.V. today announced that the Company will participate in the Capital One Securities 1st Annual Biotech/Biopharma Disrupters Event to be held in New York City.

CG Pharmaceuticals, a late-stage clinical biopharmaceutical company specializing in metastatic pancreatic ductal adenocarcinoma (PDAC) maintenance therapy (NCT05249101), will feature one of our investigators, Dr. Christos Fountzilas from Roswell Park Comprehensive Cancer Center, at the ASCO Annual Meeting in Chicago on June 1st, 1:30 – 4:30 PM CDT, during the Gastrointestinal Cancer session (TPS4206).